Catalog

Hematology Virtual Symposium February 3 & 4, 2021
Online
Added:
Credits awarded per Session. See individual Sessions for further details.
Credits awarded
Type
Name
Sub type
Value
Certificate awarded

About this item

Day 1 - Wednesday February 3, 2021: 11:00am - 2:00pm (Eastern)

Session 1: Development of Allogeneic Stem Cell Transplantation & Modern T cell Therapies

This session will give an historic overview about the development of allogeneic stem cell transplantation in context with the developments in the field of immunology, as both areas are closely linked. It will then highlight how the concept of T cell therapy was discovered and how more recent developments have emerged based on the observations from allogeneic stem cell transplantation.

Session 2: von Willebrand Disease and a Current Update of the Thrombotic Symptoms

of COVID-19 Patients

In 1926, Dr. Erik Adolf von Willebrand first described an inherited bleeding disorder that afflicted an entire family in his native Finland.  Since then, there have been several different types of von Willebrand Disease (vWD) identified which are all caused by abnormalities in the quantity or function of von Willebrand Factor (vWF), both named in honour of Dr. von Willebrand's pioneering work.  This lecture will provide a comprehensive history of the discovery and classification of vWD subtypes, as well as a current review of the role vWF plays in the thrombotic symptoms of a subset of COVID-19 patients.

Session 3: Name That Cell: Hematology Scattergrams & Cell Morphology Cases

Please join us for a Hematology Cell Morphology case study webinar.  Martine Blais and Jeremy Marks from Sysmex Canada will review some case studies and discuss how abnormal cell morphology influences scattergram patterns and flagging.

 

Day 2 - Thursday February 4, 2021: 11:00am - 2:00pm (Eastern)

Session 1: Convalescent Plasma: An old Therapeutic Tool and Possible Treatment for COVID-19

In this session we will discuss what convalescent plasma treatment is, the existing evidence and rationale for its use, as well as the history of the use of this blood product as a treatment for various viral pathogens. We will discuss how research through international clinical trials is informing our understanding of the efficacy of using convalescent plasma to treat patients sick with COVID-19. Finally, we will discuss donor centre activities regarding donor recruitment and collection of COVID-19 convalescent plasma, a precious resource given altruistically by donors recovered from COVID-19.

Session 2: Next-Generation Sequencing in Leukemia 2021

Session Description TBA

Session 3: What a ride this has been…..and it’s not over yet!

Who knew being a lab tech was going to be like this!? From the highs and the lows, to the great successes and epic failures, each experience has led me to where I am today. I want to share with all you my experiences, mistakes, accomplishments, successes, challenges, struggles and yes even my inner most secrets. I’m now halfway through my career and as I reflect back to when I first started to where I am now…..boy what a ride! Definitely excited to continue and see what the next half will look like.

 

Course/Activity Information

Day 1 - February 3, 2021

Session 1: Development of Allogeneic Stem Cell Transplantation & Modern T cell Therapies

Learning Outcomes

  • To learn how allogeneic stem cell transplantation was developed
  • To learn how the concept of T cell therapy evolved
  • To learn how this translates into recent T cell therapy approaches

Speaker: Dr. Armin Gerbitz, Cell Processing Lab (CPL), Princess Margaret Cancer Centre

Armin Gerbitz received his medical training at the University of Munich in Germany and became part of the Munich stem cell transplantation team in 1995. After his post doc at the Dana Farber Cancer Institute in Boston in1999, he continued his training at various places and eventually became attending physician at the Charite in Berlin. He continued as program director at the Charite Berlin until he moved to Canada in 2019. He currently is staff physician at the Hans Messner allogeneic stem cell transplantation Program and Medical Director of the Orsino Cell Processing Lab at Princess Margaret Cancer Centre. He is married and has two daughters who keep him honest.

 

Session 2: von Willebrand Disease and a Current Update of the Thrombotic Symptoms

of COVID-19 Patients

Learning Outcomes

  • Provide a historical account of the discovery of von Willebrand Disease (vWD)
  • Describe the function of von Willebrand Factor (vWF), an important procoagulant enzyme
  • Provide a current update of the role of vWF in the thrombotic symptoms of COVID-19 patients

Speaker: Terence Litavec, MLT

Terence Litavec is the MLT Director of the BCSLS and he has worked as a medical laboratory technologist for the past 17 years.  He currently works in the Hematology Department at LifeLabs in Burnaby, BC.  Before that, he worked at Burnaby Hospital and Kelowna General Hospital, as well as Tacoma General Hospital and PhenoPath Laboratories, both in Washington State.  He is certified by both the CSMLS and the ASCP.  He is a certified specialist in hematology and coagulation, and he also has bench experience working in immunohistochemistry, flow cytometry, transfusion services, and some molecular methods such as FISH and PCR.

 

Session 3: Name That Cell: Hematology Scattergrams & Cell Morphology Cases

Learning Outcomes

  • Evaluate CBC results through case study review of common and uncommon hematological pathologies
  • Identify abnormal lab results that may accompany disease states
  • Discuss how abnormal cell morphology influences scattergram patterns and flagging on the XN Series™ analyzers

Speakers: Jeremy Marks and Martine Blais

Martine Blais and Jeremy Marks are from the clinical applications group in Sysmex Canada.  Martine and Jeremy are experienced Medical Laboratory Technologists with over 40 years of combined experience in the laboratory and with lab diagnostic companies they have seen their share of interesting lab results.

 

Day 2 - February 4, 2021

Session 1: Convalescent Plasma: An old Therapeutic Tool and Possible Treatment for COVID-19

Learning Outcomes

  • Describe existing evidence and rationale for convalescent plasma treatment
  • Understand how research is informing our knowledge about the efficacy of convalescent plasma in treating COVID-19 patients
  • Understand donor centre activities regarding recruitment and collection of COVID-19 convalescent plasma

Speaker: Terri Foster, CBS

Terrie is a Medical Services Registered Nurse at Canadian Blood Services. She is also a nurse researcher and student at the University of Western Ontario, completing a Master’s of Science in Nursing degree, with a focus in Leadership in Health Services Delivery. Terrie’s research interests include understanding and enhancing blood donor well-being especially for marginalized groups of individuals. She is also interested in altruistic blood donor behaviour and how this applies to plasma donation specifically. Terrie is also a grateful blood recipient and will hold the hand of anyone so kind as to donate blood.

 

Session 2: Next-Generation Sequencing in Leukemia 2021

Learning Outcomes

  • Clinical relevance of next-generation sequencing at the time of diagnosis of leukemia
  • Clinical relevance of next-generation sequencing based minimal residual disease monitoring in leukemia and after allogeneic stem cell transplantation
  • Single cell sequencing technology as a future diagnostic tool in leukemia

Speaker: Dr. Dennis Kim, Princess Margaret Hospital

Dr. Dennis Kim is the Associate Professor, Department of Medical Oncology & Hematology at the Princess Margaret Cancer Centre. He graduated from Kyungpook National University, School of Medicine in Korea in 1995 and did his residency in Internal Medicine.

After working as the Assistant Professor, Division of Hematology/Oncology, Department of Medicine at the Sungkyunkwan University School of Medicine in Seoul, Korea until 2011, he came to Canada to work at the Princess Margaret Cancer Centre and has been there since. He has published over 200 peer-reviewed papers as of June 2020 and has been the Principal Investigator in multiple clinical trials.

 

Session 3: What a ride this has been…..and it’s not over yet!

Learning Outcomes

  • Identify your career goals
  • Become more knowledgeable about the career path
  • Become aware and engage opportunities that are available

Speaker: Rania Elhalabi, BSc, MLT

Rania Elhalabi BSc, MLT is a Medical Laboratory Technologist (MLT) who completed her Bachelor of Science degree at Mount Allison University then went on to complete a degree in Medical Laboratory Science. She is currently the Coagulation supervisor in the Hematology Department at the Moncton Hospital for the past eight years. Rania has volunteered both locally, provincially and nationally in her professional societies. Rania is passionate about the MLT profession and is also involved in many initiatives in her workplace.

Download the printable attachment for session times and descriptions.

Other information

Additional Charges May Apply
Close
Shopping Cart
Total:  Close

Loading Shopping Cart Items...